JPS60178820A - 抗腫瘍活性物質の製造方法 - Google Patents
抗腫瘍活性物質の製造方法Info
- Publication number
- JPS60178820A JPS60178820A JP59032199A JP3219984A JPS60178820A JP S60178820 A JPS60178820 A JP S60178820A JP 59032199 A JP59032199 A JP 59032199A JP 3219984 A JP3219984 A JP 3219984A JP S60178820 A JPS60178820 A JP S60178820A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- cartilage
- substance
- tumor
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 title claims description 4
- 230000000259 anti-tumor effect Effects 0.000 title description 6
- 210000000845 cartilage Anatomy 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 4
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 4
- 230000001376 precipitating effect Effects 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- OYULQAZWUYPDMQ-UHFFFAOYSA-N 2-(diethylamino)ethylurea Chemical compound CCN(CC)CCNC(N)=O OYULQAZWUYPDMQ-UHFFFAOYSA-N 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 11
- 239000012528 membrane Substances 0.000 abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 7
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- 241000283690 Bos taurus Species 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 5
- 239000002244 precipitate Substances 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 238000005194 fractionation Methods 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- 229920000936 Agarose Polymers 0.000 abstract description 3
- 238000000502 dialysis Methods 0.000 abstract description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 238000009795 derivation Methods 0.000 abstract 1
- 210000003754 fetus Anatomy 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 16
- 239000002504 physiological saline solution Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59032199A JPS60178820A (ja) | 1984-02-22 | 1984-02-22 | 抗腫瘍活性物質の製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59032199A JPS60178820A (ja) | 1984-02-22 | 1984-02-22 | 抗腫瘍活性物質の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60178820A true JPS60178820A (ja) | 1985-09-12 |
| JPH0573760B2 JPH0573760B2 (enExample) | 1993-10-15 |
Family
ID=12352232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59032199A Granted JPS60178820A (ja) | 1984-02-22 | 1984-02-22 | 抗腫瘍活性物質の製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60178820A (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242692A (en) * | 1990-07-10 | 1993-09-07 | Bar Ilan University | Anti-metastatic factor |
| US6168807B1 (en) | 1998-07-23 | 2001-01-02 | Les Laboratoires Aeterna Inc. | Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
| US6380366B1 (en) | 1994-04-28 | 2002-04-30 | Les Laboratoires Aeterna Inc. | Shark cartilage extract:process of making, methods of using and compositions thereof |
| US6383522B1 (en) | 1997-03-11 | 2002-05-07 | Les Laboratoires Aeterna, Inc. | Toxicity reduced composition containing an anti-neoplastic agent and a shark cartilage extract |
-
1984
- 1984-02-22 JP JP59032199A patent/JPS60178820A/ja active Granted
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242692A (en) * | 1990-07-10 | 1993-09-07 | Bar Ilan University | Anti-metastatic factor |
| US6380366B1 (en) | 1994-04-28 | 2002-04-30 | Les Laboratoires Aeterna Inc. | Shark cartilage extract:process of making, methods of using and compositions thereof |
| US6635285B2 (en) | 1994-04-28 | 2003-10-21 | Les Laboratoires Aeterna, Inc. | Shark cartilage extract: process of making, methods of using, and compositions thereof |
| US6383522B1 (en) | 1997-03-11 | 2002-05-07 | Les Laboratoires Aeterna, Inc. | Toxicity reduced composition containing an anti-neoplastic agent and a shark cartilage extract |
| US6855338B2 (en) | 1997-03-11 | 2005-02-15 | Les Laboratoires Aeterna, Inc. | Anti-tumor therapies comprising a combination of a cartilage extract and an anti-neoplastic agent providing high efficacy and low toxic side effects |
| US6168807B1 (en) | 1998-07-23 | 2001-01-02 | Les Laboratoires Aeterna Inc. | Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
| US6506414B2 (en) | 1998-07-23 | 2003-01-14 | Les Laboratoires Aeterna Inc. | Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0573760B2 (enExample) | 1993-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kay | Kidney phosphatase | |
| US4054648A (en) | Process for preparing a therapeutic agent | |
| JPH0741505A (ja) | 抗ウイルス物質 | |
| JPS62209101A (ja) | エキナセアプルプレアまたはエキナセアアングステイフオリアの細胞培養物からの免疫刺激作用性ポリサツカライド、その製造方法及びこれを含む製剤 | |
| CN109371088A (zh) | 一种海参活性肽的制备方法 | |
| DK144890B (da) | Fremgangsmaade til fremstilling af et nitrongenholdigt polysaccharid | |
| JP3092874B2 (ja) | 乳清由来の骨芽細胞増殖・骨強化画分及び該画分を含有する骨強化食品、飼料、薬品類 | |
| KR920002935B1 (ko) | 맥관 형성 저해제 | |
| US4629627A (en) | Antiviral substance and the manufacturing method thereof | |
| JPH08143462A (ja) | 免疫賦活剤及び抗腫瘍剤 | |
| Klein et al. | Investigations on the nature of haemopoietin, the anti-anaemic substance in hog's stomach: The production of a thermostable haemopoietically active substance similar to or identical with the anti-anaemic principle of liver by the action of the thermolabile haemopoietin on beef | |
| US4908206A (en) | Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them | |
| JPH0573760B2 (enExample) | ||
| Grossman et al. | Effect of heparin on fate of intravenously administered fat emulsions in rats. | |
| JP3172599B2 (ja) | 細胞賦活剤 | |
| CZ191098A3 (cs) | Způsob výroby hyaluronidázy a její použití | |
| JPH03505200A (ja) | 治療活性のある、特に傷治療または老人医学に用いる作用物質およびかかる作用物質を含む製剤の製造方法 | |
| EP1727553B1 (en) | Agent for substitution of blood plasma and a method of its production | |
| JP2714663B2 (ja) | 腸内有益菌増殖促進剤 | |
| Snellman et al. | Studies of renal urea cycle enzymes. II. Human renal arginase activity and location of the adaptive changes of renal arginase in the protein deprived rat | |
| Robbins et al. | Cholesterol and Cholate Concentration of Perfusate and Bile of Isolated Liver Preparation. | |
| JP2911097B2 (ja) | 糖タンパク質及びこれを有効成分とする食欲抑制剤 | |
| Brown et al. | Absence of antinatriferic and natriuretic activity in plasma ultrafiltrates (mol wt less than 50,000) and dialysates from volume-expanded dogs | |
| RU2175552C1 (ru) | Способ получения антикоагулянта из сапропеля | |
| JPS59186994A (ja) | 細胞形質転換増殖因子の製造法 |